Elizabeth L. Lockerman

7.5k total citations · 2 hit papers
10 papers, 1.4k citations indexed

About

Elizabeth L. Lockerman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Elizabeth L. Lockerman has authored 10 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Elizabeth L. Lockerman's work include Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Elizabeth L. Lockerman is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Elizabeth L. Lockerman collaborates with scholars based in United States and Japan. Elizabeth L. Lockerman's co-authors include Jeffrey A. Engelman, Lecia V. Sequist, Zofia Piotrowska, Matthew J. Niederst, Angel R. Garcia, Hillary E. Mulvey, Haichuan Hu, Alice T. Shaw, Luc Friboulet and Ryohei Katayama and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Clinical Cancer Research.

In The Last Decade

Elizabeth L. Lockerman

10 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

2015 441 citations Matthew J. Niederst, Haichuan Hu et al. Clinical Cancer Research profile →
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

2014 351 citations Sadhna Vora, Dejan Juric et al. Cancer Cell profile →

Peers

Countries citing papers authored by Elizabeth L. Lockerman

Since Specialization

Citations

This map shows the geographic impact of Elizabeth L. Lockerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth L. Lockerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth L. Lockerman more than expected).

Fields of papers citing papers by Elizabeth L. Lockerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth L. Lockerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth L. Lockerman. The network helps show where Elizabeth L. Lockerman may publish in the future.

Co-authorship network of co-authors of Elizabeth L. Lockerman

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth L. Lockerman. A scholar is included among the top collaborators of Elizabeth L. Lockerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth L. Lockerman. Elizabeth L. Lockerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record 2018 ·JMIR Medical Informatics ·Brian J. Wells, Kristin M. Lenoir, Franck Diaz‐Garelli, (unknown), Elizabeth L. Lockerman, Kevin M. Pantalone, Michael W. Kattan	13
2	Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer 2016 ·European Journal of Cancer ·Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, (unknown), Ryohei Katayama, Ibiayi Dagogo‐Jack, S. Gadgeel, Katherine R. Schultz, Mahendra Singh, Emily Chin, Melissa Parks, (unknown), Richard H. DiCecca, Elizabeth L. Lockerman, Tiffany G. Huynh, (unknown), Cyril H. Benes, J. A. Engelman, Alice T. Shaw	119
3	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies breakdown → 2015 ·Clinical Cancer Research ·Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman	441
4	Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways 2015 ·eLife ·S. Michael Rothenberg, Kyle Concannon, (unknown), Gaylor Boulay, Alexa B. Turke, Anthony C. Faber, Elizabeth L. Lockerman, Miguel N. Rivera, Jeffrey A. Engelman, Shyamala Maheswaran, Daniel A. Haber	36
5	Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib 2014 ·Clinical Cancer Research ·Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw	222
6	Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer 2014 ·Clinical Cancer Research ·Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita	147
7	Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Zofia Piotrowska, Matthew J. Niederst, Mari Mino–Kenudson, Vicente Morales‐Oyarvide, Linnea Fulton, Elizabeth L. Lockerman, Emily Howe, Justin F. Gainor, P. Fidias, Rebecca S. Heist, Alice T. Shaw, J. A. Engelman, Lecia V. Sequist	12
8	CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors breakdown → 2014 ·Cancer Cell ·Sadhna Vora, Dejan Juric, (unknown), Mari Mino–Kenudson, Tiffany G. Huynh, Carlotta Costa, Elizabeth L. Lockerman, Sarah F. Pollack, Manway Liu, Xiaoyan Li, Joseph Lehár, Marion Wiesmann, Markus Wartmann, Yan Chen, Z. Alexander Cao, Maria Pinzon-Ortiz, Sunkyu Kim, Robert Schlegel, Alan Huang, Jeffrey A. Engelman	351
9	Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy. 2014 ·Journal of Clinical Oncology ·Zofia Piotrowska, Matthew J. Niederst, Mari Mino–Kenudson, Vicente Morales‐Oyarvide, Linnea Fulton, Elizabeth L. Lockerman, Emily Howe, Justin F. Gainor, Panos Fidias, Subba R. Digumarthy, Rebecca S. Heist, Alice T. Shaw, Jeffrey A. Engelman, Lecia V. Sequist	7
10	Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). 2014 ·Journal of Clinical Oncology ·Justin F. Gainor, Luc Friboulet, Ryohei Katayama, Mark M. Awad, Elizabeth L. Lockerman, Katherine R. Schultz, Sidra Mahmood, Makoto Nishio, Noriko Yanagitani, Lecia V. Sequist, Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact